Abstract: A series of macrocyclic imides and Schiff-bases have been prepared via the cyclocondensation of pyridine-2,6-dicarbonyl dichloride (1) with L-ornithine methyl ester to give the corresponding macrocyclic bisester 2. Treatment of 2 with hydrazine hydrate gave macrocyclic bisacid hydrazide 3, which was used as starting material. Condensation of bishydrazide 3 with diacid anhydrides or aromatic aldehydes in refluxing acetic acid or ethanol gave the corresponding macrocyclic bisimides 4, 5a,b and macrocyclic bishydrazones 6a-j, respectively. The structure assignments of the new compounds were based on chemical and spectroscopic evidence. The antimicrobial screening showed that many of these newly synthesized compounds have good antimicrobial activities, comparable to ampicillin and ketaconazole used as reference drugs.
Introduction
Among the different areas of macrocyclic chemistry, the synthesis and complexing properties of azacrown compounds have been a subject of intensive exploration [1] [2] [3] [4] [5] [6] [7] . The chemical modification of antibacterial agents in order to generate novel macrocyclic compounds with better therapeutic properties is necessary because of the emergence of multidrug resistant bacteria [8] . On the other hand, peptides rarely function well as drugs due to their low bioavailability and rapid degradation within cells [9] . In our previous work, we reported the synthesis of some macrocyclic candidates from the reactions of dipicolinic acid with amino acids and their biological activity screening [10] [11] [12] [13] [14] . In particular, 2,6-peptidopyridines exhibited a general ionophoric potency [15] and were used for inventing novel thiocyanate-selective membrane sensors [16] . Recently, some new heterocyclic steroidal and macrocyclic derivatives have been studied as 5α-reductase inhibitors, antiviral and anti-tumor agents [17] , aromatase and quinone reductase-2 inhibitors [18] , anti-inflammatory [19] , anticonvulsant [20] and antimicrobial agents [21, 22] . In view of these observations and in continuation of our previous work in macrocyclic chemistry, we have now synthesized some new macrocyclic derivatives containing pyridine and amino acid moieties. Some of the synthesized compounds were screened for their antimicrobial activity compared to the reference drugs ampicillin and ketaconazole.
Results and Discussion

Chemistry
In our previous work, a series of chiral macrocyclic compounds were synthesized using macrocyclic bishydrazide derivative 3 [13] , which was obtained from the corresponding ester 2 according to the published procedure [23, 24] 10, 14 ]octacosa-1(26),10,12,14,23,25-hexene macrocyclic bishydrazones 6a-j (Scheme 2 and Table 1 ). The structures of newly synthesized compounds 4, 5a,b and 6a-j were confirmed by their IR, 1 H-NMR, 13 C-NMR and mass spectra. 
Antimicrobial Testing
The newly synthesized compounds have been tested for their preliminary antimicrobial activity against the following microorganisms: Gram-positive bacteria, represented by Bacillus subtilis (NRRL B-543) and Staphylococcus aureus (NRRL B-313), Gram-negative bacteria, represented by Escherichia coli (NRRL B-558) and fungi, represented by Candida albicans (NRRL Y-477) and Aspergillus niger (NRRL Y-3). The results are summarized in Table 2 . From the data it appears that some of the synthesized compounds have modest antimicrobial activity. Except for 6c, 6g (against B. subtilis) and 6d, 6e, 6h, 6i (against S. aureus) the activities of tested compounds against these Gram-positive bacteria are slightly higher than that of the reference drug ampicillin. The activities of compounds 3, 4, 5a,b, 6b, 6d, and 6g-j against the Gram negative bacterium E. coli were all similar to the activity of the reference drug, while compounds 5b, 6a, 6c, 6e and 6f are inactive against the same organism. In addition, the compounds tested against fungal organisms (C. albicans and A. niger) had lower activities than the reference drug nyastatin or, as in the case of compounds 5b, 6a, 6b, 6d, 6e and 6i, were inactive against C. albicans strain.
Experimental
General
Melting points were determined in open glass capillaries using in Electrothermal IA 9000 Series digital melting point apparatus (Electrothermal, Essex, UK) and are uncorrected. Elemental analyses were performed with all final compounds with an Elementar, Vario EL, Microanalytical Unit, National Research Centre, Cairo, Egypt and were in good agreement (±0.2%) with the calculated values. The IR spectra (KBr) were recorded on an FT IR-8201 PC spectrophotometer (Shimadzu, Tokyo, Japan). The 
Chemistry
Synthesis of Bisimidotricyclo- [3,23,1,1 11,15 ]triaconta-1(28), 11,13,15,25,27- 
hexene Derivatives 4 and 5a,b
A suspension of the hydrazide derivative 3 (0.554 g, 1 mmol) and 1,8-naphthalindicarboxylic anhydride, phthalic anhydride or 2,3,4,5-tetrachlorophthalic anhydride (2 mmol) in acetic acid (50 mL) was refluxed for 7 h. The solid was collected by filtration, washed with acetic acid and crystallized from dimethylformamide/water to give the corresponding macrocyclic octaamidodipyridyl derivatives 4 and 5a,b, respectively. 3,8,16,21,27, 28-hexaaza-2,9,15,22-tetraoxotricyclo[3,21,1,1 10,14 ]octacosa-1 (26) , 10,12,14,22,25- 10, 14 ]octacosa-1 (26) , 10,12,14,22,25- 10, 14 ]octacosa-1 (26) , 10,12,14,23,25- 
4,20-Di[oxo-2-(amino-3a,6-dihydro-1H-benzo[de]isoquinoline-1,3(2H)-dione)methyl]-
4,20-Di[oxo-2-(amino-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione)methyl]-
hexenes 6a-j
A mixture of the hydrazide derivative 3 (0.554 g, 1 mmol) and the appropriate aldehyde (2 mmol) in absolute ethanol (50 mL) was heated under reflux for 6 h. The solvent was evaporated under reduced pressure and the residue was solidified with ether. The solid was collected by filtration, washed with ether and crystallized from a proper solvent to afford the corresponding tricyclohexaazaoctacosabis-hydrazone derivatives 6a-j, respectively. -3,8,16,21,27,28-hexaaza-2,9,15,22-tetraoxotricyclo-[3,21, 1,1 10, 14 ]octacosa-1 (26) , 10,12,14,23,25- 10, 14 ]octacosa-1 (26) , 10,12,14,23,25- 10, 14 ]octacosa-1 (26) , 10,12,14,23,25- 10, 14 ]octacosa-1 (26) , 10,12,14,23,25- -3,8,16,21,27,28-hexaaza-2,9,15,22-tetraoxotricyclo [3,21,1,1 10,14 ]octacosa-1 (26) , 10,12,14,23,25- -3,8,16,21,27,28-hexaaza-2,9,15,22-tetraoxotricyclo [3,21,1,1 10,14 ]octacosa-1 (26) , 10,12,14,23,25- -3,8,16,21,27,28-hexaaza-2,9,15,22-tetraoxotricyclo [3,21,1,1 10,14 ]octacosa-1 (26) , 10,12,14,23,25- 
4,20-Di[oxphenylcarbohydrazonylmethyl)
4,20-Di[oxo-4-methylphenylcarbohydrazonylmethyl)
4,20-Di[oxo-2-methoxyphenylcarbohydrazonylmethyl)
4,20-Di[oxo-4-methoxyphenylcarbohydrazonylmethyl)
Antimicrobial Testing
The antimicrobial activity for the tested compounds was measured at 50 μg/mL, and was determined by the agar diffusion method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) [28] [29] [30] . The degree of inhibition is measured in mm in comparison with that of ampicillin and ketaconazole at the same concentration taken as standard values.
In this method, two agar media, nutrient agar for bacteria and Czapek Dox agar for fungi were prepared and sterilized by autoclaving at 120 °C and 1.5 atm. for 20 min. The agar plates were poured left to cool down and after solidification they were inoculated with the bacterial and fungal strains by streaking. The tested compounds were loaded on sterile filter paper discs (5 mm diameter) at 50 µg/mL of DMSO and transferred aseptically into the inoculated agar plates along with ampicillin and ketaconazole discs at the same concentration for comparison. The plates were then incubated at 37 °C for 24 h for bacteria and at 30 °C for 48-72 h for fungi. After incubation, the diameters of the inhibition zones around the paper discs were measured in mm as an indication of the antimicrobial activities of the compounds.
Conclusions
A series of chiral macrocyclic imides and Schiff-bases 4-6 were synthesized using as starting material the macrocyclic bis-hydrazide derivative 3 [13] , obtained from the corresponding ester 2 according to the published procedure [23, 24] . The structure assignments of the new compounds are based on chemical and spectroscopic evidence. The newly synthesized compounds have been tested for their preliminary antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi. From the results it appears that some of the synthesized compounds have modest antimicrobial activities. The activities of all tested compounds against Gram positive bacteria (B. subtilis and S. aureus) are higher than that of the reference drug except for 6c, 6g (against B. subtilis) and 6d, 6e, 6h, 6i against S. aureus. The activities of compounds 3, 4, 5a,b, 6b, 6d, and 6g-j against the Gram negative bacterium E. coli were similar to that of the reference drug, while compounds 5b, 6a, 6c, 6e and 6f are not active against the same organism. In addition, the compounds which were tested against fungal organisms (C. albicans and A. niger) had lower activities than the reference drug, or, as in the case of compounds 5b, 6a, 6b, 6d, 6e and 6i, were not active against the C. albicans strain.
